CYTOSORBENTS CORPORATION
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-4.4M | $-5.1M | $-3.2M | $1.9M | $-1.5M | $-2.8M | $-4.3M | $-6.1M |
| Depreciation & Amortization | — | — | — | — | $368.5K | — | — | $397.3K |
| Depreciation | $300.0K | $289.0K | $300.0K | $300.0K | $306.0K | $300.0K | — | $342.2K |
| Amortization | $60.0K | $61.0K | — | $60.0K | $63.0K | — | — | — |
| Stock-Based Compensation | $368.0K | $544.0K | $488.0K | $571.0K | $818.0K | $891.0K | $989.0K | $959.5K |
| Net Cash from Operating Activities | $-583.0K | $-1.2M | $-2.6M | $-1.5M | $-3.5M | $-2.5M | $-4.8M | $-4.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $14.0K | $11.0K | $17.0K | $37.0K | $2.0K | $152.0K | $17.8K | $45.2K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $-46.0K | — | — | $-47.0K | — | — | $-127.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | — | — | — | $6.8M | — | — | $-571.8K |
| Net Change in Cash | — | $-1.4M | — | — | $3.3M | — | — | $-5.5M |
| Free Cash Flow | $-597.0K | $-1.2M | $-2.6M | $-1.5M | $-3.5M | $-2.6M | $-4.8M | $-4.9M |